The clinical effectiveness and cost-effectiveness of cetuximab (mono- or combination chemotherapy), bevacizumab (combination with non-oxaliplatin chemotherapy) and panitumumab (monotherapy) for the treatment of metastatic colorectal cancer after first-line chemotherapy (review of technology appraisal No.150 and part review of technology appraisal No. 118): a systematic review and economic model-Reference-Cited by-同舟云学术

The clinical effectiveness and cost-effectiveness of cetuximab (mono- or combination chemotherapy), bevacizumab (combination with non-oxaliplatin chemotherapy) and panitumumab (monotherapy) for the treatment of metastatic colorectal cancer after first-line chemotherapy (review of technology appraisal No.150 and part review of technology appraisal No. 118): a systematic review and economic model

Published:2013-04 Issue:14 Volume:17 Page:
ISSN:1366-5278
Container-title:Health Technol Assess
language:en
Short-container-title:

Author:

Hoyle M¹,Crathorne L,Peters J,Jones-Hughes T,Cooper C,Napier M,Tappenden P,Hyde C

Affiliation:

1. Peninsula Technology Assessment Group (PenTAG), University of Exeter, Exeter, UK

Funder

National Institute for Health Research

Publisher

National Institute for Health Research

Subject

Health Policy

Cited by 53 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Nomogram for Predicting Post-progression-free Survival in Patients with Recurrent Pancreatic Ductal Adenocarcinoma after Radical Surgery;2024-05-28

2. Economic evaluations of radioembolization with yttrium-90 microspheres in liver metastases of colorectal cancer: a systematic review;BMC Gastroenterology;2023-05-24

3. Cost-effectiveness of atezolizumab versus pembrolizumab as first-line treatment in PD-L1-positive advanced non-small-cell lung cancer in Spain;Cost Effectiveness and Resource Allocation;2023-01-16

4. Linalool Impress Colorectal Cancer Deterioration by Mediating AKT/mTOR and JAK2/STAT3 Signaling Pathways;BioMed Research International;2022-07-11

5. WX-0593 combined with an epithelial growth factor receptor (EGFR) monoclonal antibody in the treatment of xenograft tumors carrying triple EGFR mutations;Annals of Translational Medicine;2022-06